Betof, A., Chesney, J. A., In, G. K., Shoushtari, A., Johnson, T. T., Moyers, J. T., Samhouri, Y., Long, G. V., Ramsingh, G., Duan, R., Prabhakar, P., McLaughlin, L., Reuter, M., Amaria, R. N. (2026). OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.9507